Cargando…

Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US

BACKGROUND: Guidelines endorse statin therapy for lowering low-density lipoprotein cholesterol (LDL-C) to recommended levels, in patients with cardiovascular disease (CVD) risk, if needed, after lifestyle changes. Atorvastatin is a common statin with greater LDL-C lowering efficacy than most other s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marrett, Elizabeth, Zhao, Changgeng, Zhang, Ning Jackie, Zhang, Qiaoyi, Ramey, Dena R, Tomassini, Joanne E, Tershakovec, Andrew M, Neff, David R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4008284/ https://www.ncbi.nlm.nih.gov/pubmed/24851051 http://dx.doi.org/10.2147/VHRM.S54886

Ejemplares similares

Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy
por: Foody, JoAnne M, et al.
Publicado: (2013)

Effect of Switching From Statin Monotherapy to Ezetimibe/Simvastatin Combination Therapy Compared With Other Intensified Lipid‐Lowering Strategies on Lipoprotein Subclasses in Diabetic Patients With Symptomatic Cardiovascular Disease
por: Le, Ngoc‐Anh, et al.
Publicado: (2015)

Relationships Between Metabolic Syndrome and Other Baseline Factors and the Efficacy of Ezetimibe/Simvastatin and Atorvastatin in Patients With Type 2 Diabetes and Hypercholesterolemia
por: Goldberg, Ronald B., et al.
Publicado: (2010)

Time-related trends in variability of cIMT changes in statin trials
por: Davidson, Michael H., et al.
Publicado: (2015)

Changes in Lipoprotein Particle Number With Ezetimibe/Simvastatin Coadministered With Extended‐Release Niacin in Hyperlipidemic Patients
por: Le, Ngoc‐Anh, et al.
Publicado: (2013)

Comparing the combination therapy of ezetimibe and atorvastatin with atorvastatin monotherapy for regulating blood lipids: a systematic review and meta-analyse
por: Ai, Cong, et al.
Publicado: (2018)

Assessment of severity and frequency of self-reported hypoglycemia on quality of life in patients with type 2 diabetes treated with oral antihyperglycemic agents: A survey study
por: Marrett, Elizabeth, et al.
Publicado: (2011)

Burden of peripheral arterial disease in Europe and the United States: a patient survey
por: Marrett, Elizabeth, et al.
Publicado: (2013)

Atorvastatin 10 mg plus ezetimibe versus titration to atorvastatin 40 mg: attainment of European and Canadian guideline lipid targets in high-risk subjects ≥65 years
por: Constance, Christian, et al.
Publicado: (2014)

Atorvastatin treatment and LDL cholesterol target attainment in patients at very high cardiovascular risk
por: Laufs, Ulrich, et al.
Publicado: (2016)

Risk Factors for Atorvastatin as a Monotherapy for Chronic Subdural Hematoma: A Retrospective Multifactor Analysis
por: Zhang, Xinjie, et al.
Publicado: (2021)

The comparative efficacy of ezetimibe added to atorvastatin 10 mg versus uptitration to atorvastatin 40 mg in subgroups of patients aged 65 to 74 years or greater than or equal to 75 years
por: Ben-Yehuda, Ori, et al.
Publicado: (2011)

Short-term use of atorvastatin affects glucose homeostasis and suppresses the expression of LDL receptors in the pancreas of mice
por: Yu, Qi, et al.
Publicado: (2018)

Effect of Extended-Release Niacin on New-Onset Diabetes Among Hyperlipidemic Patients Treated With Ezetimibe/Simvastatin in a Randomized Controlled Trial
por: Guyton, John R., et al.
Publicado: (2012)

Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey
por: Krempf, Michel, et al.
Publicado: (2015)

Bioactivity of Dietary Polyphenols: The Role in LDL-C Lowering
por: Sun, Peng, et al.
Publicado: (2021)

Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a)
por: Deshmukh, Harshal A., et al.
Publicado: (2012)

Physician Reasons for Nonpharmacologic Treatment of Hyperglycemia in Older Patients Newly Diagnosed with Type 2 Diabetes Mellitus
por: Marrett, Elizabeth, et al.
Publicado: (2012)

Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia
por: Kumar, Shoba Sujana, et al.
Publicado: (2009)

A comparison of the effects of monotherapy with rosuvastatin, atorvastatin or ezetimibe versus combination treatment with rosuvastatin-ezetimibe and atorvastatin-ezetimibe on the integrity of vascular endothelial cells damaged by oxidized cholesterol
por: Niedzielski, Mateusz, et al.
Publicado: (2021)

Response by sex to statin plus ezetimibe or statin monotherapy: A pooled analysis of 22,231 hyperlipidemic patients
por: Abramson, Beth L, et al.
Publicado: (2011)

Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents
por: Konrad, Robert J, et al.
Publicado: (2011)

Awareness, Treatment, and Control of LDL Cholesterol Are Lower Among U.S. Adults With Undiagnosed Diabetes Versus Diagnosed Diabetes
por: Brown, Todd M., et al.
Publicado: (2013)

Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk
por: Rosen, Jeffrey B., et al.
Publicado: (2015)

Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy
por: Insull, William, et al.
Publicado: (2010)

Reasons given by general practitioners for non-treatment decisions in younger and older patients with newly diagnosed type 2 diabetes mellitus in the United Kingdom: a survey study
por: Zhang, Qiaoyi, et al.
Publicado: (2011)

Effects of Rosuvastatin and Atorvastatin on LDL and HDL Particle Concentrations in Patients With Metabolic Syndrome: A randomized, double-blind, controlled study
por: Rosenson, Robert S., et al.
Publicado: (2009)

Integrated analysis of long noncoding RNA and mRNA profiling ox-LDL-induced endothelial dysfunction after atorvastatin administration
por: Jiang, Ling-Yu, et al.
Publicado: (2018)

Cardiovascular mortality after intensive LDL-Cholesterol lowering: Does baseline LDL-Cholesterol really matter?
por: Khan, Safi U., et al.
Publicado: (2020)

Atorvastatin and sildenafil lower blood pressure and improve endothelial dysfunction, but only atorvastatin increases vascular stores of nitric oxide in hypertension()
por: Guimarães, Danielle A., et al.
Publicado: (2013)

Lipid-lowering therapies and achievement of LDL-cholesterol targets
por: Rizzo, Manfredi, et al.
Publicado: (2012)

Efficacy and safety of Zhibitai in combination with atorvastatin for lipid lowering in patients with coronary heart disease
por: Xu, Danyan, et al.
Publicado: (2017)

ASCOT analysis with atorvastatin shows limits of CRP as indicator of cardiovascular risk
Publicado: (2011)

Cholesteryl Ester Transfer Protein Gene and Effectiveness of Lipid Lowering of Atorvastatin
por: Kolovou, Genovefa, et al.
Publicado: (2010)

Atorvastatin-induced pancreatitis
por: Prajapati, Samir, et al.
Publicado: (2010)

LDL-C: lower is better for longer—even at low risk
por: Penson, Peter E., et al.
Publicado: (2020)

New and emerging lipid-modifying drugs to lower LDL cholesterol
por: Kosmas, Constantine E, et al.
Publicado: (2021)

LDL lowering effect of PCSK9 inhibition is reduced in women
por: Myasoedova, Veronika A, et al.
Publicado: (2023)

Effectiveness of low-intensity atorvastatin 5 mg and ezetimibe 10 mg combination therapy compared with moderate-intensity atorvastatin 10 mg monotherapy: A randomized, double-blinded, multi-center, phase III study
por: Lee, Seung-Ah, et al.
Publicado: (2023)

Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapy
por: Toth, Peter P, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_03cm3uoiis58tpfdvbrdd8nk2v